Background: Postmarketing surveillance studies (PMS) are an important tool for evaluating a drugs effectiveness and safety in clinical practice. To our knowledge, no PMS on memantine monotherapy for moderately-severe-to-severe Alzheimers disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke Alzheimers Disease and Related Disorders Association criteria has been conducted to date. Objective: The Lombardy Health Office, Italy, promoted this PMS to evaluate the effectiveness and safety of memantine in the treatment of moderately-severe-to-severe AD in clinical practice. Methods: A total of 451 patients with moderately-severe-to-severe AD (meanage 77 7 years; 72% female), free of cholinergic medication, received memantine (standard titration to 10 mg twice daily). After 6 months of therapy, treatment effectiveness was evaluated according to two definitions of response (no deterioration and improvement), as measured by changes in baseline scores on the Clinical Global Impression of Change, Mini-Mental State Examination, Neuropsychiatric Inventory and Activities of Daily Living scales. The safety measure was the frequency of adverse events (AEs). Results: At 6-month assessment, 26.8% of subjects showed no deterioration and 3.8% showed improvement. In those showing no deterioration, response to treatment at the 3-month assessment was associated with a greater probability of a response at 6 months (adjusted odds ratio = 8.54; 95% CI 4.54, 16.05). Seventy patients (15.5%) experienced at least one AE and 39 (8.6%) discontinued treatment prematurely because of an AE. Of those who experienced an AE, 27 (38.6%) manifested behavioural and psychological symptoms of dementia. Conclusion: The proportion of responders to memantine treatment in this PMS was similar to that reported in a previous randomized clinical trial (26.8% vs 29%, respectively). The proportion of patients who discontinued treatment prematurely because of an AE (8.6%) was similar to that reported in two previous randomized clinical trials (10% and 12.4%). This PMS provides additional evidence that both the effectiveness and the tolerability of memantine may be transferred into real world medicine, where AD patients receiving treatment are not selected according to strict criteria. © 2009 Adis Data Information BV. All rights reserved.

Clerici, F., Vanacore, N., Elia, A., Spila Alegiani, S., Pomati S, D., Raschetti, R., et al. (2009). Memantine in moderately-severe-to-severe Alzheimer's disease: a post-marketing surveillance study. DRUGS & AGING, 26(4), 321-332 [10.2165/00002512-200926040-00003].

Memantine in moderately-severe-to-severe Alzheimer's disease: a post-marketing surveillance study

APPOLLONIO, ILDEBRANDO;ISELLA, VALERIA;BELLELLI, GIUSEPPE;
2009

Abstract

Background: Postmarketing surveillance studies (PMS) are an important tool for evaluating a drugs effectiveness and safety in clinical practice. To our knowledge, no PMS on memantine monotherapy for moderately-severe-to-severe Alzheimers disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke Alzheimers Disease and Related Disorders Association criteria has been conducted to date. Objective: The Lombardy Health Office, Italy, promoted this PMS to evaluate the effectiveness and safety of memantine in the treatment of moderately-severe-to-severe AD in clinical practice. Methods: A total of 451 patients with moderately-severe-to-severe AD (meanage 77 7 years; 72% female), free of cholinergic medication, received memantine (standard titration to 10 mg twice daily). After 6 months of therapy, treatment effectiveness was evaluated according to two definitions of response (no deterioration and improvement), as measured by changes in baseline scores on the Clinical Global Impression of Change, Mini-Mental State Examination, Neuropsychiatric Inventory and Activities of Daily Living scales. The safety measure was the frequency of adverse events (AEs). Results: At 6-month assessment, 26.8% of subjects showed no deterioration and 3.8% showed improvement. In those showing no deterioration, response to treatment at the 3-month assessment was associated with a greater probability of a response at 6 months (adjusted odds ratio = 8.54; 95% CI 4.54, 16.05). Seventy patients (15.5%) experienced at least one AE and 39 (8.6%) discontinued treatment prematurely because of an AE. Of those who experienced an AE, 27 (38.6%) manifested behavioural and psychological symptoms of dementia. Conclusion: The proportion of responders to memantine treatment in this PMS was similar to that reported in a previous randomized clinical trial (26.8% vs 29%, respectively). The proportion of patients who discontinued treatment prematurely because of an AE (8.6%) was similar to that reported in two previous randomized clinical trials (10% and 12.4%). This PMS provides additional evidence that both the effectiveness and the tolerability of memantine may be transferred into real world medicine, where AD patients receiving treatment are not selected according to strict criteria. © 2009 Adis Data Information BV. All rights reserved.
No
Articolo in rivista - Articolo scientifico
Scientifica
Demenza; malattia di Alzheimer; memantina
English
Clerici, F., Vanacore, N., Elia, A., Spila Alegiani, S., Pomati S, D., Raschetti, R., et al. (2009). Memantine in moderately-severe-to-severe Alzheimer's disease: a post-marketing surveillance study. DRUGS & AGING, 26(4), 321-332 [10.2165/00002512-200926040-00003].
Clerici, F; Vanacore, N; Elia, A; Spila Alegiani, S; Pomati S, D; Raschetti, R; Mariani, C; Memantine Lombardy Study, G; Altavilla, R; Appollonio, I; Isella, V; Avanzi, S; Bargnani, C; Bascelli, C; Bellelli, G; Guerini, F; Belotti, G; Bottini, G; Gerini, M; Cheldi, A; Bellotti, M; Chia, F; Cislaghi, G; Cusi, C; Mesina, M; Cuzzoni, G; Farina, E; Alberoni, M; Franceschi, M; Zucchi, M; Guerini, M; Iori, T; Lanza, E; Finotti, M; Lucchelli, F; Maggiore, L; Ratti, P; Magnani, G; Schiatti, E; Marcone, A; Giusti, M; Margarito, F; Martina, A; Mauri, M; Merlo, P; Mazza, S; Moleri, M; Riva, R; Montecalvo, G; Chinaglia, C; Engaddi, I; Perini, M; Carnicelli, A; Petro, E; Pettenati, C; Perotta, D; Ranzenigo, A; Bertozzi, B; Redaelli, L; Reverberi, F; Salvi, G; Manzoni, L; Saviotti, F; Scarpini, E; Guidi, I; Sinforiani, E; Zucchella, C; Tagliavini, F; Marcon, G; Turla, M; Viti, N; Zanetti, O; Alberici, A
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/10446
Citazioni
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 18
Social impact